Although CB2 has been established as antisteatogenic in alcohol-mediated liver disease by reducing steatogenic cytokines in CB2-stimulated Kuppfer cells, its role in NAFLD is controversial [42]. This evidence concerns the gene CNR2 and metabolic dysfunction-associated steatotic liver disease.